Session Type: ePosters
Session Title: ePosters
Authors(s): C.G. Carvalhaes, H.S. Sader, J.M. Streit, M. Castanheira, R.E. Mendes
Authors Affiliations(s): JMI Laboratories, United States
Background:
Enterococcus faecalis (EF) and Enterococcus faecium (EFM) cause difficult-to-treat infections due to their intrinsic and acquired resistance to many antimicrobials. This study evaluated the activity of oritavancin and comparators against a contemporary collection of Enterococcus spp. clinical isolates from European centres.
Methods:3,596 Enterococcus isolates were collected in Western Europe (W-EU; n=3,114; 10 countries) and Eastern Europe (E-EU; n=482; 5 countries) during 2015-2019. Bacteria were identified by standard microbiology methods and/or MALDI-TOF. Susceptibility testing was performed by the reference broth microdilution method; MIC interpretation used EUCAST and CLSI criteria, except for oritavancin (breakpoint for vancomycin-susceptible EF applied to all isolates) and daptomycin that used CLSI criteria.
Results:EF (n=2,182) and EFM (n=1,304) comprised >95% of the collection. Vancomycin resistance (VRE) was noted in 0.9% and 19.6% of the isolates, respectively. The VRE rate was higher in E-EU (13.7%) than W-EU (7.1%). VanA was the most common phenotype (78.7% of all VREs), regardless of species or geographic region, whereas the VanB phenotype was more frequently observed among VRE-EFM isolates from W-EU (n=45, 23.1%) than E-EU (n=4, 6.6%). Only 2 (10.5%) EF met the criteria for a VanB phenotype, as opposed to 49 EFM (19.1%). Oritavancin was active against EF isolates (MIC50/90, 0.015/0.03 mg/L, 99.3% susceptible) and against 57.9% (11/19) of VRE isolates. EF displayed high susceptibility to ampicillin (100%), linezolid (99.9%), daptomycin (99.6%), and vancomycin (99.1%). In this setting of multi-resistant pathogens, oritavancin was active against 100.0% of both daptomycin non-susceptible (n=9) and linezolid-resistant (n=2) EF subsets. Linezolid (99.7%) and daptomycin (100% susceptible dose-dependent) remained active against EFM isolates, as did oritavancin (MIC50/90, 0.004/0.015 mg/L) inhibiting 99.9% of EFM isolates at ≤0.12 mg/L, including 99.6% of VRE (n=256) isolates and 75% of linezolid-resistant (n=4) EFM subsets. Oritavancin inhibited 96.0% and 100.0% of all enterococci displaying the VanA and VanB phenotypes, respectively, at MIC of ≤0.12 mg/L.
Conclusions:Oritavancin was very active against this contemporary collection of Enterococcus isolates from Europe, including isolates non-susceptible to daptomycin, and/or resistant to ampicillin, linezolid, and vancomycin. VRE and VanB phenotypes varied among European regions, while VanA remains the most common phenotype across all regions.
Keyword(s): E. faecalis, E. faecium, lipoglycopeptidesCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by A. Menarini Industrie Farmaceutiche Riunite S.R.L., which included funding for services related to preparing this abstract.
Session Type: ePosters
Session Title: ePosters
Authors(s): C.G. Carvalhaes, H.S. Sader, J.M. Streit, M. Castanheira, R.E. Mendes
Authors Affiliations(s): JMI Laboratories, United States
Background:
Enterococcus faecalis (EF) and Enterococcus faecium (EFM) cause difficult-to-treat infections due to their intrinsic and acquired resistance to many antimicrobials. This study evaluated the activity of oritavancin and comparators against a contemporary collection of Enterococcus spp. clinical isolates from European centres.
Methods:3,596 Enterococcus isolates were collected in Western Europe (W-EU; n=3,114; 10 countries) and Eastern Europe (E-EU; n=482; 5 countries) during 2015-2019. Bacteria were identified by standard microbiology methods and/or MALDI-TOF. Susceptibility testing was performed by the reference broth microdilution method; MIC interpretation used EUCAST and CLSI criteria, except for oritavancin (breakpoint for vancomycin-susceptible EF applied to all isolates) and daptomycin that used CLSI criteria.
Results:EF (n=2,182) and EFM (n=1,304) comprised >95% of the collection. Vancomycin resistance (VRE) was noted in 0.9% and 19.6% of the isolates, respectively. The VRE rate was higher in E-EU (13.7%) than W-EU (7.1%). VanA was the most common phenotype (78.7% of all VREs), regardless of species or geographic region, whereas the VanB phenotype was more frequently observed among VRE-EFM isolates from W-EU (n=45, 23.1%) than E-EU (n=4, 6.6%). Only 2 (10.5%) EF met the criteria for a VanB phenotype, as opposed to 49 EFM (19.1%). Oritavancin was active against EF isolates (MIC50/90, 0.015/0.03 mg/L, 99.3% susceptible) and against 57.9% (11/19) of VRE isolates. EF displayed high susceptibility to ampicillin (100%), linezolid (99.9%), daptomycin (99.6%), and vancomycin (99.1%). In this setting of multi-resistant pathogens, oritavancin was active against 100.0% of both daptomycin non-susceptible (n=9) and linezolid-resistant (n=2) EF subsets. Linezolid (99.7%) and daptomycin (100% susceptible dose-dependent) remained active against EFM isolates, as did oritavancin (MIC50/90, 0.004/0.015 mg/L) inhibiting 99.9% of EFM isolates at ≤0.12 mg/L, including 99.6% of VRE (n=256) isolates and 75% of linezolid-resistant (n=4) EFM subsets. Oritavancin inhibited 96.0% and 100.0% of all enterococci displaying the VanA and VanB phenotypes, respectively, at MIC of ≤0.12 mg/L.
Conclusions:Oritavancin was very active against this contemporary collection of Enterococcus isolates from Europe, including isolates non-susceptible to daptomycin, and/or resistant to ampicillin, linezolid, and vancomycin. VRE and VanB phenotypes varied among European regions, while VanA remains the most common phenotype across all regions.
Keyword(s): E. faecalis, E. faecium, lipoglycopeptidesCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by A. Menarini Industrie Farmaceutiche Riunite S.R.L., which included funding for services related to preparing this abstract.
JMI Laboratories
Session Type: ePosters
Session Title: ePosters
Authors(s): C.G. Carvalhaes, H.S. Sader, J.M. Streit, M. Castanheira, R.E. Mendes
Authors Affiliations(s): JMI Laboratories, United States
Background:
Enterococcus faecalis (EF) and Enterococcus faecium (EFM) cause difficult-to-treat infections due to their intrinsic and acquired resistance to many antimicrobials. This study evaluated the activity of oritavancin and comparators against a contemporary collection of Enterococcus spp. clinical isolates from European centres.
Methods:3,596 Enterococcus isolates were collected in Western Europe (W-EU; n=3,114; 10 countries) and Eastern Europe (E-EU; n=482; 5 countries) during 2015-2019. Bacteria were identified by standard microbiology methods and/or MALDI-TOF. Susceptibility testing was performed by the reference broth microdilution method; MIC interpretation used EUCAST and CLSI criteria, except for oritavancin (breakpoint for vancomycin-susceptible EF applied to all isolates) and daptomycin that used CLSI criteria.
Results:EF (n=2,182) and EFM (n=1,304) comprised >95% of the collection. Vancomycin resistance (VRE) was noted in 0.9% and 19.6% of the isolates, respectively. The VRE rate was higher in E-EU (13.7%) than W-EU (7.1%). VanA was the most common phenotype (78.7% of all VREs), regardless of species or geographic region, whereas the VanB phenotype was more frequently observed among VRE-EFM isolates from W-EU (n=45, 23.1%) than E-EU (n=4, 6.6%). Only 2 (10.5%) EF met the criteria for a VanB phenotype, as opposed to 49 EFM (19.1%). Oritavancin was active against EF isolates (MIC50/90, 0.015/0.03 mg/L, 99.3% susceptible) and against 57.9% (11/19) of VRE isolates. EF displayed high susceptibility to ampicillin (100%), linezolid (99.9%), daptomycin (99.6%), and vancomycin (99.1%). In this setting of multi-resistant pathogens, oritavancin was active against 100.0% of both daptomycin non-susceptible (n=9) and linezolid-resistant (n=2) EF subsets. Linezolid (99.7%) and daptomycin (100% susceptible dose-dependent) remained active against EFM isolates, as did oritavancin (MIC50/90, 0.004/0.015 mg/L) inhibiting 99.9% of EFM isolates at ≤0.12 mg/L, including 99.6% of VRE (n=256) isolates and 75% of linezolid-resistant (n=4) EFM subsets. Oritavancin inhibited 96.0% and 100.0% of all enterococci displaying the VanA and VanB phenotypes, respectively, at MIC of ≤0.12 mg/L.
Conclusions:Oritavancin was very active against this contemporary collection of Enterococcus isolates from Europe, including isolates non-susceptible to daptomycin, and/or resistant to ampicillin, linezolid, and vancomycin. VRE and VanB phenotypes varied among European regions, while VanA remains the most common phenotype across all regions.
Keyword(s): E. faecalis, E. faecium, lipoglycopeptidesCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by A. Menarini Industrie Farmaceutiche Riunite S.R.L., which included funding for services related to preparing this abstract.
Session Type: ePosters
Session Title: ePosters
Authors(s): C.G. Carvalhaes, H.S. Sader, J.M. Streit, M. Castanheira, R.E. Mendes
Authors Affiliations(s): JMI Laboratories, United States
Background:
Enterococcus faecalis (EF) and Enterococcus faecium (EFM) cause difficult-to-treat infections due to their intrinsic and acquired resistance to many antimicrobials. This study evaluated the activity of oritavancin and comparators against a contemporary collection of Enterococcus spp. clinical isolates from European centres.
Methods:3,596 Enterococcus isolates were collected in Western Europe (W-EU; n=3,114; 10 countries) and Eastern Europe (E-EU; n=482; 5 countries) during 2015-2019. Bacteria were identified by standard microbiology methods and/or MALDI-TOF. Susceptibility testing was performed by the reference broth microdilution method; MIC interpretation used EUCAST and CLSI criteria, except for oritavancin (breakpoint for vancomycin-susceptible EF applied to all isolates) and daptomycin that used CLSI criteria.
Results:EF (n=2,182) and EFM (n=1,304) comprised >95% of the collection. Vancomycin resistance (VRE) was noted in 0.9% and 19.6% of the isolates, respectively. The VRE rate was higher in E-EU (13.7%) than W-EU (7.1%). VanA was the most common phenotype (78.7% of all VREs), regardless of species or geographic region, whereas the VanB phenotype was more frequently observed among VRE-EFM isolates from W-EU (n=45, 23.1%) than E-EU (n=4, 6.6%). Only 2 (10.5%) EF met the criteria for a VanB phenotype, as opposed to 49 EFM (19.1%). Oritavancin was active against EF isolates (MIC50/90, 0.015/0.03 mg/L, 99.3% susceptible) and against 57.9% (11/19) of VRE isolates. EF displayed high susceptibility to ampicillin (100%), linezolid (99.9%), daptomycin (99.6%), and vancomycin (99.1%). In this setting of multi-resistant pathogens, oritavancin was active against 100.0% of both daptomycin non-susceptible (n=9) and linezolid-resistant (n=2) EF subsets. Linezolid (99.7%) and daptomycin (100% susceptible dose-dependent) remained active against EFM isolates, as did oritavancin (MIC50/90, 0.004/0.015 mg/L) inhibiting 99.9% of EFM isolates at ≤0.12 mg/L, including 99.6% of VRE (n=256) isolates and 75% of linezolid-resistant (n=4) EFM subsets. Oritavancin inhibited 96.0% and 100.0% of all enterococci displaying the VanA and VanB phenotypes, respectively, at MIC of ≤0.12 mg/L.
Conclusions:Oritavancin was very active against this contemporary collection of Enterococcus isolates from Europe, including isolates non-susceptible to daptomycin, and/or resistant to ampicillin, linezolid, and vancomycin. VRE and VanB phenotypes varied among European regions, while VanA remains the most common phenotype across all regions.
Keyword(s): E. faecalis, E. faecium, lipoglycopeptidesCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by A. Menarini Industrie Farmaceutiche Riunite S.R.L., which included funding for services related to preparing this abstract.